Breaking News Instant updates and real-time market news.

TXMD

TherapeuticsMD

$2.73

-0.25 (-8.39%)

, VFF

Village Farms

$13.44

-0.17 (-1.25%)

08:45
08/15/19
08/15
08:45
08/15/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: TherapeuticsMD (TXMD) 62.61% +9.78, Village Farms International (VFF) 19.92% +0.50, NextEra Energy (NEE) 0.49% +0.16, United Technologies (UTX) 0.41% +0.16, Fitbit (FIT) 0.65% +0.13, NIO (NIO) 34.76% +0.10, Frontier Communications (FTR) 21.35% +0.07, Eldorado Resorts (ERI) 1.00% +0.05, Microchip (MCHP) 0.36% +0.05, and Tilray (TLRY) 34.48% +0.04.

TXMD

TherapeuticsMD

$2.73

-0.25 (-8.39%)

VFF

Village Farms

$13.44

-0.17 (-1.25%)

NEE

NextEra Energy

$214.98

-0.47 (-0.22%)

UTX

United Technologies

$123.53

-4.7 (-3.67%)

FIT

Fitbit

$3.10

-0.2 (-6.07%)

NIO

NIO Inc.

$2.90

-0.255 (-8.10%)

FTR

Frontier Communications

$0.68

-0.0973 (-12.59%)

ERI

Eldorado Resorts

$39.55

-1.02 (-2.51%)

MCHP

Microchip

$86.86

-3.48 (-3.85%)

TLRY

Tilray

$39.13

-6.925 (-15.04%)

  • 15

    Aug

  • 20

    Aug

  • 06

    Sep

  • 10

    Sep

  • 23

    Sep

  • 02

    Oct

TXMD TherapeuticsMD
$2.73

-0.25 (-8.39%)

08/07/19
CANT
08/07/19
NO CHANGE
Target $13
CANT
Overweight
Cantor reiterates $13 price target on TherapeuticsMD after 'solid' quarter
Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on TherapeuticsMD with a $13 price target following the company's "solid quarter of execution." TherapeuticsMD in premarket trading is up 10%, or 18c, to $2.05. Upward earnings revisions and multiple expansion to levels not reflected in consensus forecasts will drive the stock higher, Chen tells investors in a research note. The analyst anticipates better than expected uptake for Imvexxy, Bijuva and Annovera in 2019 and beyond.
06/25/19
STFL
06/25/19
NO CHANGE
STFL
Evolus can benefit from 'distraction' at Allergan, says Stifel
After AbbVie (ABBV) announced its intention to acquire Allergan (AGN), Stifel analyst Annabel Samimy said the former clearly sees the latter's Medical Aesthetics business "as a premier, durable, cash-pay franchise and a leader in its field." However, she noted that AbbVie committed to keeping it as a separate business under the Allergan name, which leads Samimy to believe that a spinoff of aesthetics remains a possibility. She also said she would expect "meaningful distraction" at Allergan, "as typical in the midst of an acquisition," which can benefit competitor Evolus (EOLS) as it launches Jeuveau. Samimy, who concluded that she sees today's news potentially bringing interest back to the "washed out" biopharma group, names Revance (RVNC), Aerie Pharmaceuticals (AERI), TherapeuticsMD (TXMD) and Kala Pharmaceuticals (KALA) as being among the potentially attractive targets.
06/12/19
CANT
06/12/19
NO CHANGE
Target $13
CANT
Overweight
TherapeuticsMD price target lowered to $13 from $27 at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen lowered her price target for TherapeuticsMD to $13 from $27, driven by multiple contraction, given increasing headwinds from macro factors. The analyst reiterates an Overweight rating on the shares.
07/15/19
JEFF
07/15/19
NO CHANGE
Target $3
JEFF
Hold
TherapeuticsMD price target lowered to $3 from $4 at Jefferies
Jefferies analyst Chris Howerton lowered his price target for TherapeuticsMD to $3 from $4 following the company's recent 2019 guidance and clarity on Annovera. The analyst's base-case for Annovera assumes new contraceptive category status and peak estimates of 35%, $315M, and 60% for penetration, revenue and net margin, respectively. He says the guidance gives him pause and keeps a Hold rating on the shares.
VFF Village Farms
$13.44

-0.17 (-1.25%)

06/13/19
ROTH
06/13/19
INITIATION
Target $25
ROTH
Buy
Village Farms initiated with a Buy at Roth Capital
Roth Capital analyst Scott Fortune started coverage of Village Farms with a Buy rating and $25 price target. The analyst notes that the company is converting its 10.6M sq. ft. tomato greenhouse infrastructure in North America, to new profitable cannabis/hemp cultivation. Established distribution and relationships with the biggest U.S. retailers allow potential new CBD product sales, he contends, adding that Village Farms can easily convert into cannabis cultivation once federally legal in the U.S. and Mexico.
07/22/19
CHLM
07/22/19
INITIATION
Target $30
CHLM
Buy
Village Farms initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Eric Des Lauriers initiated Village Farms with a Buy rating and a price target of $30, saying the company is becoming a "dominant" cannabis cultivator and has a large opportunity in U.S. hemp space. The analyst notes that Village Farms is exceeding cannabis yield and quality expectations and believes the company has a low-cost path to becoming a dominant cultivator, with potential to "far exceed" consensus estimates beginning in 2020.
NEE NextEra Energy
$214.98

-0.47 (-0.22%)

08/13/19
08/13/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pampa Energia (PAM) downgraded to Equal Weight from Overweight at Morgan Stanley and to Neutral from Buy at BofA/Merrill. 2. NextEra Energy (NEE) and Xcel Energy (XEL) downgraded to Equal Weight from Overweight at Barclays. 3. Seadrill (SDRL) downgraded to Neutral from Buy at BTIG with analyst Gregory Lewis saying the company emerged from bankruptcy with too much debt, and its options to increase liquidity are costlier today than they were last year owing to increasing concerns about the pace of the recovery of offshore drilling. 4. Occidental downgraded to Underweight from Neutral at JPMorgan with analyst Phil Gresh reinstated coverage of Occidental Petroleum following a period of restriction and downgraded the shares to Underweight from Neutral, saying despite the 33% stock price decline since before the Anadarko deal was announced, Occidental's total return potential of 15% is roughly half that of the peer group. 5. SPX Flow (FLOW) downgraded to Neutral from Buy at Seaport Global with analyst Walt Liptak saying he believes that the company will be impacted by sector slowing in its Food & Beverage and Industrial segments. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/13/19
LEHM
08/13/19
DOWNGRADE
Target $218
LEHM
Equal Weight
NextEra Energy downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Eric Beaumont downgraded NextEra Energy to Equal Weight from Overweight with an unchanged price target of $218.
08/13/19
MSCO
08/13/19
NO CHANGE
Target $234
MSCO
Overweight
NextEra Energy price target raised to $234 from $207 at Morgan Stanley
Morgan Stanley analyst Stephen Byrd said NextEra Energy is the beneficiary of "two powerful trends," namely cheap renewable energy and low interest rates. NextEra, a pioneer in the U.S. renewables sector, has consistently had a leading market share in both wind and solar and the company's return on invested capital for these areas has remained attractive over a very long period, said Byrd, who added that renewable technologies continue to drop in cost "at a rapid rate." Meanwhile, he contends that investors do not fully appreciate that NextEra is one of the biggest indirect beneficiaries from a "lower for longer" interest rate world, Byrd stated. Given these two factors, he raised his price target on NextEra shares to $234 from $207 and keeps an Overweight rating on the stock.
08/13/19
LEHM
08/13/19
DOWNGRADE
Target $218
LEHM
Equal Weight
Barclays downgrades NextEra Energy to Equal Weight after outperformance
Barclays analyst Eric Beaumont downgraded NextEra Energy to Equal Weight from Overweight with an unchanged price target of $218. The analyst continues to see NextEra as a "premium company with top-tier" earnings growth. However, since late 2018, the shares have meaningfully outperformed peers, says the analyst. He believes a neutral rating better reflects the current risk/reward in the shares.
UTX United Technologies
$123.53

-4.7 (-3.67%)

06/24/19
06/24/19
UPGRADE

Outperform
United Technologies upgraded to Outperform from Market Perform at Cowen
As previously reported, Cowen analyst Cai von Rumohr upgraded United Technologies (UTX) to Outperform from Market Perform following the selloff in the shares after the Raytheon (RTN) merger announcement. The analyst raised his price target on United Technologies shares to $150 from $135. The analyst was positive on the "attractive" proposed Raytheon merger, seeing synergies in hypersonics, directed energy, ISR, cyber protection for connected aircraft, and air traffic control. The analyst also liked United Technologies for the "extended Aerospace cash ramp," as they see a likely multiyear margin/cash flow ramp in that space.
06/24/19
06/24/19
DOWNGRADE

Neutral
Raytheon downgraded to Neutral from Buy at Buckingham
As previously reported, Buckingham analyst Richard Safran downgraded Raytheon (RTN) to Neutral from Buy and lowered his price target on the shares to $195 from $265. The analyst said that initially he was neutral on the deal with United Technologies (UTX), which Buckingham does not cover, but now believes it is a solid deal for United Technologies that "possibly undervalues" Raytheon. Safran added that until the deal is either completed or denied by the Pentagon, Raytheon shares will now be tied to United Technologies.
06/24/19
06/24/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. United Technologies (UTX) upgraded to Outperform from Market Perform at Cowen with analyst Cai von Rumohr citing the selloff in the shares after the Raytheon (RTN) merger announcement. 2. Deere (DE) and Agco (AGCO) upgraded to Buy from Hold at Jefferies. 3. Rent-A-Center (RCII) upgraded to Equal Weight from Underweight at Stephens with analyst Vincent Caintic citing what he sees as "massive potential" for third-party retailer Rent-To-Own, telling investors that he wouldn't want to be short any Rent-To-Own stock he covers as a result. 4. Hostess Brands (TWNK) upgraded to Buy from Neutral at UBS with Steven Strycula citing three catalysts he sees. 5. Dunkin' Brands (DNKN) upgraded to Outperform from Neutral at Wedbush with analyst Nick Steyan saying he believes Dunkin' U.S. is currently undergoing an inflection in same-store sales growth that is underappreciated by the Street. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/08/19
JPMS
07/08/19
DOWNGRADE
Target $231
JPMS
Underweight
JPMorgan's Tusa downgrades Lennox to Underweight with $231 price target
JPMorgan analyst Stephen Tusa downgraded Lennox International (LII) to Underweight from Neutral with an unchanged price target of $231. The analyst this morning also upgraded Johnson Controls (JCI) to Neutral from Underweight. Lennox's standing premium to implied HVAC multiples "at soon to be pure play peers seems overdone," Tusa tells investors in a research note. The analyst believes the emergence of two new pure plays, "seemingly currently trading at ~30% discounts," dilutes Lennox's scarcity value. Tusa's price target implies 20% downside versus his Overweight-rated HVAC related names, Ingersoll-Rand (IR) and United Technologies (UTX).
FIT Fitbit
$3.10

-0.2 (-6.07%)

08/01/19
SBSH
08/01/19
NO CHANGE
Target $2
SBSH
Sell
Fitbit price target lowered to $2 from $5 at Citi
Citi analyst Jim Suva lowered his price target for Fitbit to $2 from $5 saying the Q3 guidance miss "on all metrics" overshadowed the company's Q2 results. Fitbit's current tangible book value is $2.13, contends the analyst, who projects the tangible book value to be $2.02 in a year from now. His main concern with Fitbit continues to be that the company lacks a mass appeal smartwatch with full two-way texting functionality, such as the Apple Watch. He keeps a Sell rating on the shares.
05/15/19
DADA
05/15/19
NO CHANGE
Target $7
DADA
Buy
Fitbit healthcare story 'underappreciated', says DA Davidson
DA Davidson analyst Tom Forte kept his Buy rating and $7 price target on Fitbit (FIT), citing the company's latest partnering announcement with the UnitedHealthcare's (UNH) Motion effort through its Charge 3 tracker device participation. The analyst believes that the announcement is just the "latest example" in Fitbit's integration efforts within the healthcare ecosystem and sees it as a "huge differentiator" within the sector where investors look at products as "merely commodities."
04/05/19
DADA
04/05/19
NO CHANGE
Target $7
DADA
Buy
Fitbit's Snap partnership a positive, says DA Davidson
DA Davidson analyst Tom Forte kept his Buy rating and $7 price target on Fitbit (FIT) after it announced a Bitmoji partnership with Snap (SNAP) that allows users to access Bitmoji avatars on the face of their Fitbit smartwatches. The analyst says the deal is a positive for Fitbit as it seeks to increase customer engagement and "make personal health more fun".
02/28/19
02/28/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Fitbit (FIT) upgraded to Buy from Neutral at DA Davidson analyst Tom Forte citing Q4 results and outlook for Q1 and FY19. 2. Hain Celestial (HAIN) upgraded to Overweight from Neutral at JPMorgan with analyst Ken Goldman citing the company's "compelling" investor day, the analyst has increased confidence in Hain's ability to drive margin growth over the next few years. 3. Athene Holding (ATH) upgraded to Outperform from Market Perform at BMO Capital with analyst James Fotheringham saying the valuation multiple on the stock may have finally passed its trough at its current 5.5-times two-year forward earnings multiple and believes that its core business should be valued at 6.4-times. 4. Wabco (WBC) upgraded to Neutral from Underweight at JPMorgan and to Hold from Sell at Vertical Research. 5. Globus Medical (GMED) upgraded to Buy from Neutral at UBS with analyst Matthew Taylor saying the company has delivered several quarters in a row of improving spine growth, which confirms robot placements are leading to implant pull-through. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
NIO NIO Inc.
$2.90

-0.255 (-8.10%)

05/29/19
05/29/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. General Mills (GIS) downgraded to Sell from Neutral at Goldman Sachs with analyst Jason English saying that after a period of outperformance from sequential improvement in the company's core business and the impact of its acquisition of Blue Buffalo, General Mills is entering its next "chapter" of "mounting deceleration." 2. NIO Inc. (NIO) downgraded to Underperform from Neutral at BofA/Merrill with analyst Ming Hsun Lee saying he expects weak orders for the ES8 and ES6 due to EV purchase subsidy cuts, less cash flow from reduced car sales, increased competition from Tesla's (TSLA) Model 3 in 2020, and views valuation as "rich." 3. American Campus (ACC) downgraded to Market Perform from Outperform at JMP Securities with analyst Aaron Hecht saying his firm's checks at UC Berkeley indicate that the 6,000 bed RFP will likely end up being fee-based development, which takes one of his previously expected catalysts off the table. 4. Atlassian (TEAM) downgraded to Neutral from Buy at BTIG with analyst Edward Parker saying after a "great run" of over 100% in the last 12 months, the risk-reward on the stock has turned more "balanced." 5. Ericsson (ERIC) downgraded to Sell from Neutral at New Street. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/29/19
05/29/19
DOWNGRADE
Target $3

Underperform
NIO Inc. downgraded to Underperform on shipment downside at BofA/Merrill
As previously reported, BofA/Merrill downgraded NIO Inc. (NIO) to Underperform from Neutral and cut its price target to $3 from $6.20. Analyst Ming Hsun Lee expects weak orders for the ES8 and ES6 due to EV purchase subsidy cuts, less cash flow from reduced car sales, increased competition from Tesla's (TSLA) Model 3 in 2020, and views valuation as "rich." Lee lowered his volume sales forecast for 2019 by 20% to 27k units and 2020 by 45% to 40k units.
05/28/19
BOFA
05/28/19
DOWNGRADE
BOFA
Underperform
NIO Inc. downgraded to Underperform from Neutral at BofA/Merrill
04/04/19
04/04/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Facebook (FB) upgraded to Buy from Neutral at Guggenheim with analyst Michael Morris saying investors will continue to gain comfort with the incremental financial risk created by Facebook's content and privacy concerns. 2. NIO Inc. (NIO) upgraded to Buy from Neutral at Citi and to Neutral from Underperform at BofA/Merrill. 3. Ingersoll-Rand (IR) upgraded to Buy from Neutral at BofA/Merrill with analyst Andrew Obin citing premium core and earnings growth. 4. EOG Resources (EOG) upgraded to Buy from Hold at Tudor Pickering. 5. Signature Bank (SBNY) upgraded to Overweight from Neutral at JPMorgan with analyst Steven Alexopoulos raising his price target for the shares to $150 from $133. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
FTR Frontier Communications
$0.68

-0.0973 (-12.59%)

02/19/19
RAJA
02/19/19
DOWNGRADE
RAJA
Market Perform
Frontier Communications downgraded to Market Perform at Raymond James
02/19/19
RAJA
02/19/19
DOWNGRADE
RAJA
Market Perform
Frontier Communications downgraded to Market Perform at Raymond James
Raymond James analyst Frank Louthan downgraded Frontier Communications (FTR) to Market Perform from Outperform saying the negative Windstream (WIN) ruling will have a negative impact from a trading perspective. Louthan said rural ILECs tend to trade as a group and are overly correlated with each other regardless of their results.
06/20/19
SBSH
06/20/19
NO CHANGE
Target $1
SBSH
Sell
Frontier Communications price target lowered to $1.00 from $1.50 at Citi
Citi analyst Michael Rollins lowered his price target for Frontier Communications to $1.00 from $1.50 after incorporating a 25% risk of financial distress into his valuation analysis. While the recent asset sale was a "modest positive," recent press reports regarding informal discussions with bondholders suggests risk of financial distress is rising for Frontier, Rollins tells investors in a research note. Further, the analyst believes the appointment of two new board members who specialize in financial restructurings also increases the risk that Frontier may consider how to proactively restructure its balance sheet. He keeps a Sell rating on the shares.
01/08/19
WELS
01/08/19
DOWNGRADE
Target $1.75
WELS
Underperform
Frontier downgraded to Underperform from Market Perform at Wells Fargo
Wells Fargo analyst Jennifer Fritzsche downgraded Frontier Communications (FTR) to Underperform and lowered her price target for the shares to $1.75 from $5.00. The analyst also downgraded the Rural Local Exchange Carrier sector to Underweight from Market Weight. Frontier has reportedly been working with an advisor on how it might handle upcoming debt maturities, Fritzsche tells investors in a research note. The debt seems to be pricing in a looming restructuring, which "could cause a scar on the RLEC industry," adds the analyst. Fritzsche remains concerned about Frontier's near term balance sheet obligations and believe "this is very much a debt story at this point."
ERI Eldorado Resorts
$39.55

-1.02 (-2.51%)

06/25/19
MSCO
06/25/19
DOWNGRADE
Target $12.5
MSCO
Equal Weight
Caesars downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Thomas Allen downgraded Caesars (CZR) to Equal Weight from Overweight with a $12.50 price target after the company agreed to be acquired by Eldorado Resorts (ERI). While he sees a potential bull case to $15 per share where the market values Caesars at Friday's multiples inclusive of the greater than $500M of synergies expected for the merger, Allen said he also sees a less likely bear case of $9 per share if the deal were to fall apart.
07/01/19
WELS
07/01/19
UPGRADE
Target $24.5
WELS
Outperform
VICI Properties upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Jeffrey Donnelly upgraded VICI Properties (VICI) to Outperform from Market Perform and raised his price tare for the shares to $24.50 from $23. The company's recent partnership announcement with Eldorado Resorts (ERI) will increase its rent base by $252.5M, Donnelly tells investors in a research note. The analyst believes the deal is positive for VICI given its 6% earnings accretion, improved lease terms, and replenished pipeline for future acquisitions. In addition, the continued institutionalization of the gaming real estate investment trust sector should allow for more cap rate compression within the asset class over time, says Donnelly.
07/24/19
SUSQ
07/24/19
INITIATION
Target $50
SUSQ
Neutral
Eldorado Resorts initiated with a Neutral at Susquehanna
Susquehanna analyst Joseph Stauff initiated Eldorado Resorts with a Neutral rating and $50 price target, stating that it is "stuck" in a deal process until 2020. While he believes synergy estimates are conservative, the "market won't pay for them until deal risk is very low," contends Stauff.
07/01/19
DBAB
07/01/19
NO CHANGE
Target $74
DBAB
Buy
Eldorado Resorts price target raised to $74 from $56 at Deutsche Bank
Deutsche Bank analyst Carlo Santarelli raised his price target for Eldorado Resorts (ERI) to $74 from $56 following the company's acquisition of Caesars Entertainment (CZR). The combined entity, from a financial perspective, "harmonizes nicely" and generates "considerable" free cash flow, which, if valued properly relative to peers, implies "meaningful upside" in the shares, Santarelli tells investors in a research note. He keeps a Buy rating on both Eldorado and Caesars.
MCHP Microchip
$86.86

-3.48 (-3.85%)

07/24/19
RHCO
07/24/19
NO CHANGE
Target $133
RHCO
Hold
Texas Instruments price target raised to $133 from $122 at SunTrust
SunTrust analyst William Stein raised his price target on Texas Instruments (TXN) to $133 after its Q2 earnings beat, but kept his Hold rating, saying bottom in fundamentals for semiconductor names is being extended to Q3 from Q2. The analyst also contends that the recovery in Texas Instruments is "mostly priced in", favoring semi sector stocks that have recently underperformed such as NXP Semi (NXPI), Microchip (MCHP), and Broadcom (AVGO).
07/29/19
WELS
07/29/19
NO CHANGE
Target $115
WELS
Outperform
Microchip price target raised to $115 from $105 at Wells Fargo
Wells Fargo analyst Gary Mobley raised his price target for Microship to $115 from $105 ahead of quarterly results and based on higher valuation multiples for peers versus when he launched coverage on back in June, and his belief the near-term non-GAAP EPS consensus can move slightly higher following Q1 2020 results. The analyst reiterates an Outperform rating on the shares.
07/09/19
LBOW
07/09/19
INITIATION
LBOW
Neutral
Microchip initiated with a Neutral at Longbow
Longbow started Microchip Technology with a Neutral rating.
07/01/19
SBSH
07/01/19
NO CHANGE
SBSH
Citi sees semiconductor sector trading higher on lift of Huawei ban
Citi analyst Christopher Danely expects the semiconductor sector to trade higher after President Trump over the weekend lifted the ban on selling to Huawei and stated the U.S. would not go through with the additional $300B in tariffs. The analyst maintains his positive stance on the group and keeps a Buy ratings on Broadcom (AVGO), Microchip (MCHP), ON Semiconductor (ON) and Texas Instruments (TXN).
TLRY Tilray
$39.13

-6.925 (-15.04%)

07/17/19
LTCO
07/17/19
INITIATION
LTCO
Neutral
Tilray initiated with a Neutral at Ladenburg
Ladenburg Thalmann analyst Glenn Mattson started Tilray with a Neutral rating. Within the cannabis space, the analyst favors Canadian companies who are focused on long-term value creation and gaining market share as well as those with a well-defined plan for potentially entering the U.S. market. He initiated coverage on the cannabis space with a "bullish long-term outlook." A significant portion of Tilray's near-term growth is a result of its Manitoba acquisition, which is mainly an organic foods company, as opposed to growth from cannabis, Mattson tells investors in a research note.
08/15/19
VERF
08/15/19
NO CHANGE
Target $4
VERF
Sell
Vertical Group sees 90% downside in Tilray, says 'back up truck' to short
It is time to "back up the truck" and short shares of Tilray, Vertical Group analyst Gordon Johnson tells investors in a research note. The analyst introduced a year-end 2020 price target of $4, which implies around 90% downside to Tilray's closing price Wednesday of $39.04. The company's top shareholder, Privateer, is set to unload its 72% position over the course of this year and next, Johnson points out. Further, the analyst calls Tilray's Q2 results "horrific." On top of that, the company, which only has two-to-three quarters of cash left, admitted its results are slated to get worse, adds Johnson. The analyst says that in his years covering stocks, he's rarely seen such a richly valued company.
08/14/19
BNCH
08/14/19
NO CHANGE
Target $80
BNCH
Buy
Tilray price target lowered to $80 from $200 at Benchmark
Benchmark analyst Mike Hickey lowered his price target on Tilray shares to $80 from $200 after the company reported "mixed" Q2 results. The company's "near term profitability aspirations have been abandoned" as Tilray seeks to take additional market share, said Hickey, who remains cautious on the Canadian regulatory regime and expects on-going supply and distribution constraints. However, he keeps a Buy rating on Tilray shares.
08/14/19
STFL
08/14/19
NO CHANGE
Target $38
STFL
Hold
Stifel keeps Hold rating, $38 price target on Tilray after Q2 report
Stifel analyst W. Andrew Carter said Tilray's Q2 revenue performance exceeded his expectations and he believes the company's report underscores the cannabis industry's preeminent theme - namely, robust revenue growth opportunity bumping up against a high degree of investment needed to capitalize on a "once-in-a-lifetime" opportunity. Following the report, he increased his FY19 gross revenue estimate to $171M, but lowered his EBITDA estimates to conform more closely to the company's guidance. Carter keeps a Hold rating and $38 price target on Tilray shares, but said he thinks the stock could come under pressure as he believes investors may focus on the wider than expected EBITDA losses.

TODAY'S FREE FLY STORIES

TGT

Target

$102.13

16.555 (19.35%)

13:52
08/21/19
08/21
13:52
08/21/19
13:52
Recommendations
Target analyst commentary  »

Target price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

JMIA

Jumia Technologies

$12.43

-2.26 (-15.38%)

13:47
08/21/19
08/21
13:47
08/21/19
13:47
Recommendations
Jumia Technologies analyst commentary  »

Jumia's report…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

13:45
08/21/19
08/21
13:45
08/21/19
13:45
General news
Breaking General news story  »

FOMC Minutes to be…

AFL

Aflac

$49.66

-2.2 (-4.24%)

13:38
08/21/19
08/21
13:38
08/21/19
13:38
Periodicals
Aflac reiterates review being done of Post channel sales, Bloomberg says »

Aflac reiterated that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,823.96

21.88 (1.21%)

, WMT

Walmart

$112.15

0.03 (0.03%)

13:37
08/21/19
08/21
13:37
08/21/19
13:37
Periodicals
Amazon opens 'largest campus yet' in south Indian city, Bloomberg says »

According to an earlier…

AMZN

Amazon.com

$1,823.96

21.88 (1.21%)

WMT

Walmart

$112.15

0.03 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 25

    Sep

  • 27

    Oct

  • 13

    Nov

  • 14

    Nov

CBL

CBL & Associates

$0.86

0.022 (2.62%)

13:32
08/21/19
08/21
13:32
08/21/19
13:32
Hot Stocks
CBL Properties to pursue measures to cure NYSE rule non-compliance »

CBL Properties announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
08/21/19
08/21
13:25
08/21/19
13:25
Conference/Events
The Food & Drug Law Institute to hold a webinar »

Anthony Anscombe, Partner…

13:25
08/21/19
08/21
13:25
08/21/19
13:25
Conference/Events
FOMC releases minutes from July 30-31, 2019 Policy Meeting »

The Federal Open Market…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
08/21/19
08/21
13:17
08/21/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,195.07

11.64 (0.98%)

, GOOGL

Alphabet Class A

$1,196.08

11.82 (1.00%)

13:16
08/21/19
08/21
13:16
08/21/19
13:16
Hot Stocks
YouTube Premium users can now listen directly within Waze app »

In an earlier blog post,…

GOOG

Alphabet

$1,195.07

11.64 (0.98%)

GOOGL

Alphabet Class A

$1,196.08

11.82 (1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Oct

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
08/21/19
08/21
13:16
08/21/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHC

Bausch Health

$22.31

1.05 (4.94%)

13:06
08/21/19
08/21
13:06
08/21/19
13:06
Hot Stocks
Bausch Health trades up after VP Humphries buys over $650K in shares »

Bausch Health VP William…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 23

    Sep

FB

Facebook

$185.03

1.27 (0.69%)

, TWTR

Twitter

$42.65

0.355 (0.84%)

13:05
08/21/19
08/21
13:05
08/21/19
13:05
On The Fly
#SocialStocks: New 'Off-Facebook Activity' tool, Argus upgrades Pinterest »

Welcome to…

FB

Facebook

$185.03

1.27 (0.69%)

TWTR

Twitter

$42.65

0.355 (0.84%)

PINS

Pinterest

$36.40

2.05 (5.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

ALXN

Alexion

$113.91

2.49 (2.23%)

13:05
08/21/19
08/21
13:05
08/21/19
13:05
Options
Alexion call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 02

    Oct

  • 19

    Oct

VIOT

Viomi Technology

$9.00

-0.27 (-2.91%)

12:57
08/21/19
08/21
12:57
08/21/19
12:57
Initiation
Viomi Technology initiated at Needham »

Viomi Technology assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

MAS

Masco

$40.58

0.95 (2.40%)

, GWW

Grainger

$276.25

4.29 (1.58%)

12:57
08/21/19
08/21
12:57
08/21/19
12:57
Periodicals
Masco trades higher after Bloomberg report on bidders for cabinet-making unit »

Late in the trading…

MAS

Masco

$40.58

0.95 (2.40%)

GWW

Grainger

$276.25

4.29 (1.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

  • 23

    Oct

PFPT

Proofpoint

$117.13

5.14 (4.59%)

12:55
08/21/19
08/21
12:55
08/21/19
12:55
Conference/Events
Proofpoint participates in a conference call with Wedbush »

Software Analyst Koenig…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 28

    Aug

  • 28

    Aug

  • 05

    Sep

  • 10

    Oct

  • 15

    Oct

  • 13

    Nov

  • 12

    Dec

  • 16

    Dec

BLK

BlackRock

$420.88

2.92 (0.70%)

12:54
08/21/19
08/21
12:54
08/21/19
12:54
Periodicals
BlackRock funds get approval to acquire stake in Cofense, WSJ reports »

The Committee on Foreign…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

GS

Goldman Sachs

$200.90

0.98 (0.49%)

12:52
08/21/19
08/21
12:52
08/21/19
12:52
Periodicals
Goldman Sachs studying sale of Safe-Guard Products unit, Reuters reports »

Goldman Sachs is working…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

JNJ

Johnson & Johnson

$131.60

1.03 (0.79%)

, LLY

Eli Lilly

$111.90

0.94 (0.85%)

12:26
08/21/19
08/21
12:26
08/21/19
12:26
Periodicals
HHS appeals ruling over pharma prices in TV ads, STAT News reports »

The U.S. Department of…

JNJ

Johnson & Johnson

$131.60

1.03 (0.79%)

LLY

Eli Lilly

$111.90

0.94 (0.85%)

MRK

Merck

$87.16

1.5 (1.75%)

PFE

Pfizer

$35.04

0.42 (1.21%)

SNY

Sanofi

$43.35

0.76 (1.78%)

AZN

AstraZeneca

$45.59

0.97 (2.17%)

GSK

GlaxoSmithKline

$40.85

0.59 (1.47%)

NVS

Novartis

$90.50

1.43 (1.61%)

RHHBY

Roche

$0.00

(0.00%)

BMY

Bristol-Myers

$47.65

0.02 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 21

    Aug

  • 26

    Aug

  • 27

    Aug

  • 28

    Aug

  • 02

    Sep

  • 03

    Sep

  • 04

    Sep

  • 06

    Sep

  • 06

    Sep

  • 09

    Sep

  • 09

    Sep

  • 16

    Sep

  • 16

    Sep

  • 19

    Sep

  • 20

    Sep

  • 23

    Sep

  • 25

    Sep

  • 01

    Oct

  • 02

    Oct

  • 15

    Oct

  • 23

    Oct

  • 29

    Oct

  • 04

    Nov

NVRO

Nevro

$84.55

1.57 (1.89%)

12:25
08/21/19
08/21
12:25
08/21/19
12:25
Conference/Events
Nevro participates in a conference call with SVB Leerink »

SVB Leerink holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 26

    Aug

  • 09

    Sep

VG

Vonage

$13.53

0.185 (1.39%)

, FIVN

Five9

$64.11

1.63 (2.61%)

12:25
08/21/19
08/21
12:25
08/21/19
12:25
Conference/Events
Stephens Cloud Infrastructure Analyst to hold Analyst/Industry conference call »

Enterprise & Cloud…

VG

Vonage

$13.53

0.185 (1.39%)

FIVN

Five9

$64.11

1.63 (2.61%)

TWLO

Twilio

$132.21

5.32 (4.19%)

WORK

Slack Technologies

$31.07

0.575 (1.89%)

AMZN

Amazon.com

$1,824.00

21.92 (1.22%)

MSFT

Microsoft

$138.82

1.57 (1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 04

    Sep

  • 04

    Sep

  • 05

    Sep

  • 10

    Sep

  • 27

    Oct

  • 13

    Nov

AAPL

Apple

$213.25

2.9 (1.38%)

, FB

Facebook

$185.05

1.29 (0.70%)

12:21
08/21/19
08/21
12:21
08/21/19
12:21
Periodicals
Trump says relationship better with Apple CEO than other tech execs, CNBC says »

CNBC's Eamon Javers…

AAPL

Apple

$213.25

2.9 (1.38%)

FB

Facebook

$185.05

1.29 (0.70%)

AMZN

Amazon.com

$1,824.53

22.45 (1.25%)

GOOGL

Alphabet Class A

$1,195.80

11.54 (0.97%)

GOOG

Alphabet

$1,195.03

11.6 (0.98%)

TWTR

Twitter

$42.78

0.485 (1.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 21

    Aug

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
08/21/19
08/21
12:17
08/21/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IGLD

Internet Gold

$24.80

-0.75 (-2.94%)

12:16
08/21/19
08/21
12:16
08/21/19
12:16
Hot Stocks
Internet Gold announces receipt of Nasdaq non-compliance notice »

Internet Gold announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.